|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
|
US8999943B2
(en)
*
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
|
EP1871426B1
(en)
|
2005-04-15 |
2017-06-07 |
The Regents of The University of California |
Small activating rna molecules and their use
|
|
WO2007086990A2
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
|
JP5713377B2
(ja)
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
|
|
ES2911034T3
(es)
|
2006-08-08 |
2022-05-17 |
Univ Bonn Rheinische Friedrich Wilhelms |
Estructura y uso de oligonucleótidos 5' fosfato
|
|
AU2008308499A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agRNA and gapmers targeting antisense transcripts
|
|
WO2009099942A2
(en)
*
|
2008-01-31 |
2009-08-13 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides and uses thereof
|
|
WO2009141146A1
(en)
|
2008-05-21 |
2009-11-26 |
Gunther Hartmann |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
|
CA2732343C
(en)
*
|
2008-07-29 |
2017-05-09 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
|
CN102239260B
(zh)
*
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
|
US20110294870A1
(en)
*
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
WO2010121956A1
(en)
|
2009-04-21 |
2010-10-28 |
Basf Plant Science Company Gmbh |
Rna-mediated induction of gene expression in plants
|
|
US20120047602A1
(en)
|
2009-04-21 |
2012-02-23 |
Basf Plant Science Company Gmbh |
RNA-Mediated Induction of Gene Expression in Plants
|
|
WO2010124231A2
(en)
*
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
JP5931720B2
(ja)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
|
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
EP2446037B1
(en)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
|
CN102712925B
(zh)
|
2009-07-24 |
2017-10-27 |
库尔纳公司 |
通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
|
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
|
CN104313027B
(zh)
|
2009-08-11 |
2018-11-20 |
库尔纳公司 |
通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
|
|
KR101805213B1
(ko)
|
2009-08-21 |
2017-12-06 |
큐알엔에이, 인크. |
Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료
|
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
US20120295952A1
(en)
|
2009-09-25 |
2012-11-22 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー，インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
|
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
|
ES2585829T3
(es)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
|
|
CA2785727C
(en)
|
2009-12-31 |
2020-01-07 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
CA2785832A1
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
|
JP6027893B2
(ja)
|
2010-01-11 |
2016-11-16 |
カッパーアールエヌエー，インコーポレイテッド |
性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
|
|
EP2529015B1
(en)
|
2010-01-25 |
2017-11-15 |
CuRNA, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
ES2664585T3
(es)
|
2010-05-26 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA
|
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー，インコーポレイテッド |
Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
|
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
|
WO2012046085A2
(en)
|
2010-10-08 |
2012-04-12 |
Mina Therapeutics Limited |
Methods of inducing insulin production
|
|
KR101865433B1
(ko)
|
2010-10-22 |
2018-07-13 |
큐알엔에이, 인크. |
알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
|
|
CA2817256A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
PH12013501969B1
(en)
|
2011-03-29 |
2018-08-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
|
KR102043422B1
(ko)
|
2011-06-09 |
2019-11-11 |
큐알엔에이, 인크. |
프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
MX365525B
(es)
|
2011-09-06 |
2019-06-06 |
Curna Inc |
Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
|
|
HK1210211A1
(en)
|
2012-03-15 |
2016-04-15 |
科纳公司 |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
WO2013173652A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
CA2921556A1
(en)
*
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating rna
|
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
US20180305689A1
(en)
|
2015-04-22 |
2018-10-25 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
BR112018012237A2
(pt)
*
|
2015-12-15 |
2018-12-04 |
Sarepta Therapeutics Inc |
conjugados oligonucleotídeos-peptídeos
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
US20200339987A1
(en)
|
2017-11-09 |
2020-10-29 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining expression of the lect2 gene
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20210254069A1
(en)
|
2018-06-15 |
2021-08-19 |
Mina Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220281911A1
(en)
|
2019-08-19 |
2022-09-08 |
Mina Therapeutics Limited |
Oligonucleotide conjugate compositions and methods of use
|
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
|
PE20220604A1
(es)
*
|
2019-09-20 |
2022-04-25 |
Ractigen Therapeutics |
Molecula de acido nucleico para el tratamiento de la trombocitopenia y uso de la misma
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
|
JP2023521094A
(ja)
|
2020-04-07 |
2023-05-23 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｓｃｎ９ａ発現をサイレンシングするための組成物および方法
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
EP4329777A1
(en)
|
2021-04-28 |
2024-03-06 |
MiNA Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
|
JP2024538859A
(ja)
|
2021-08-31 |
2024-10-24 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2025052098A1
(en)
|
2023-09-08 |
2025-03-13 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
WO2025224036A1
(en)
|
2024-04-22 |
2025-10-30 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|